paclitaxel accord paclitaxel 300 mg/50 ml concentrated injection vial
accord healthcare pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol absolute - - primary treatment of ovarian cancer in combination with a platinum agent. - treatment of metastatic carcinoma of the ovary after failure of standard therapy. - treatment of metastatic carcinoma of the breast after failure of standard therapy. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. - in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. - for the treatment of non-small cell lung cancer (nsclc).
bio-moxifloxacin tablet
biomed pharma - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones
paclitaxel accord paclitaxel 30 mg/5 ml concentrated injection vial
accord healthcare pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol absolute - - primary treatment of ovarian cancer in combination with a platinum agent.. - treatment of metastatic carcinoma of the ovary after failure of standard therapy.. - treatment of metastatic carcinoma of the breast after failure of standard therapy.. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin?), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease.. - in combination with gemcitabine (gemzar?), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - for the treatment of non-small cell lung cancer (nsclc).
paclitaxel accord paclitaxel 100 mg/16.7 ml concentrated injection vial
accord healthcare pty ltd - paclitaxel, quantity: 100 mg - injection, concentrated - excipient ingredients: ethanol absolute; peg-35 castor oil - - primary treatment of ovarian cancer in combination with a platinum agent.. - treatment of metastatic carcinoma of the ovary after failure of standard therapy.. - treatment of metastatic carcinoma of the breast after failure of standard therapy.. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin?), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease.. - in combination with gemcitabine (gemzar?), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - for the treatment of non-small cell lung cancer (nsclc).
dbl gemcitabine injection gemcitabine (as hydrochloride) 2g/52.6ml solution for injection vial
pfizer australia pty ltd - gemcitabine hydrochloride, quantity: 2.277 g - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - dbl gemcitabine injection is indicated: 1. for treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). 2. for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. 3. for treatment of patients with fu refractory pancreatic cancer. 4. alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. 5. in combination with paclitaxel, for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. 6. in combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
paclitaxel kabi paclitaxel 300 mg/50 ml concentrated injection vial
fresenius kabi australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; citric acid; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).
paclitaxel kabi paclitaxel 100 mg/16.7 ml concentrated injection vial
fresenius kabi australia pty ltd - paclitaxel, quantity: 100.2 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).
paclitaxel kabi paclitaxel 30 mg/5 ml concentrated injection vial
fresenius kabi australia pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; citric acid; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).
paclitaxin paclitaxel 150 mg/25 ml concentrated injection vial
teva pharma australia pty ltd - paclitaxel, quantity: 150 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent.. treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy.. adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their metatastic disease.. paclitaxin, in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or . metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. treatment of non-small cell lung cancer (nsclc).
paclitaxin paclitaxel 300 mg/50 ml concentrated injection vial
teva pharma australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent.. treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy.. adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their metatastic disease.. paclitaxin, in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or . metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. treatment of non-small cell lung cancer (nsclc).